Articles with the topic: featured

How many is too many? Exploring the toxic CAG threshold in the Huntington’s disease brain

How many is too many? Exploring the toxic CAG threshold in the Huntington’s disease brain

New work from researchers in London uses mice to narrow in on the number of CAG repeats needed to cause symptoms of Huntington’s disease. Their work points to fewer than 185 CAGs as a threshold.

Dr Chris KayApril 21, 2024

Cry your eyes out: detecting huntingtin in tears

Cry your eyes out: detecting huntingtin in tears

Is someone cutting onions? Expanded huntingtin can now be detected in tears to help scientists track disease progression.

Dr Sarah HernandezApril 10, 2024

The director’s cut: how CAG repeats change the editing of genetic messages

The director’s cut: how CAG repeats change the editing of genetic messages

Scientists in Massachusetts have recently advanced our understanding of how repetitive sequences in DNA can disrupt the creation and editing of genetic messenger molecules in cells, and how this could lead to the production of harmful proteins.

Lucy CouplandMarch 26, 2024

Understanding expansions at the single cell level

Understanding expansions at the single cell level

Scientists have looked at CAG expansions in brains from people with HD to see which cells are affected

Dr Rachel HardingMarch 12, 2024

Huntington's Disease Therapeutics Conference 2024 - Day 3

Huntington's Disease Therapeutics Conference 2024 - Day 3

Dr Rachel Harding, Dr Leora Fox, and Dr Sarah HernandezMarch 07, 2024

Huntington's Disease Therapeutics Conference 2024 - Day 2

Huntington's Disease Therapeutics Conference 2024 - Day 2

Dr Leora Fox, Dr Sarah Hernandez, and Dr Rachel HardingMarch 06, 2024

Huntington's Disease Therapeutics Conference 2024 - Day 1

Huntington's Disease Therapeutics Conference 2024 - Day 1

Check out research updates from Day 1 of the 2024 HD Therapeutics Conference #HDTC2024

Dr Leora Fox, Dr Rachel Harding, and Dr Sarah HernandezMarch 05, 2024

CRISPR-based drugs: one giant leap for mankind

CRISPR-based drugs: one giant leap for mankind

Casgevy is the first CRISPR-based drug to make its way through the approval process, all but curing Sickle Cell Disease and it’s paving the way for similar drugs targeting other diseases. Is Huntington’s disease next?

Dr Sarah HernandezFebruary 14, 2024

Putting it in print: GENERATION HD1 study results published

Putting it in print: GENERATION HD1 study results published

Data from GENERATION HD1, the Phase 3 clinical trial testing the huntingtin-lowering drug tominersen, have just been published in a scientific journal. The trial ended a while back, so why is this an important milestone, and what’s next?

Dr Leora Fox, Dr Rachel Harding, and Dr Sarah HernandezDecember 07, 2023

Donate

Please consider making a donation if you value the services that HDBuzz provides. We want HDBuzz to be sustainable so that we can continue to report unbiased science to the HD community.

With your support, we can ensure the continuity of our services. Nothing is expected, but everything is appreciated and sustains what we do at HDBuzz. Please consider giving what you're able. More information...